CN104072758A - Functional polyethylene glycol (PEG) for medicine - Google Patents
Functional polyethylene glycol (PEG) for medicine Download PDFInfo
- Publication number
- CN104072758A CN104072758A CN201410331977.1A CN201410331977A CN104072758A CN 104072758 A CN104072758 A CN 104072758A CN 201410331977 A CN201410331977 A CN 201410331977A CN 104072758 A CN104072758 A CN 104072758A
- Authority
- CN
- China
- Prior art keywords
- peg
- benzyl
- polyalkylene glycol
- tyr
- functional polyalkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses functional polyethylene glycol (PEG) for medicine. A preparation method of the functional PEG comprises the steps: synthesizing three-arm PEG from epoxyethane, which serves as a raw material, by using alkaline-process ring opening; preparing a macromolecular initiator; carrying out ring opening polymerization on the macromolecular initiator and O-benzyl-L-tyrosine carboxylic anhydride (NCA), so as to obtain a star-shaped block polymer which takes PEG as a core and PNCA as arms; and adding polytyrosine with low molecular weight, and dissolving the block copolymer by using the amphiphilic nature of the block copolymer, thereby forming a nano-scale porous material. The block copolymer has a hexagonal columnar structure, and a continuous phase is PEG, so that the material is provided with nano-scale pores. The material has the following advantages that the material is provided with nano-scale micropores; the defect of the traditional linear PEG materials that the processability is poor is overcome; the material is free from toxic and side effects; the material can serve as a drug carrier material; the material can serve as a medical implant material; and the material can serve as a component material for in-vivo sustained medication devices.
Description
Technical field
The present invention relates to a kind of preparation method who can be used as the porous polyoxyethylene glycol of pharmaceutical carrier, particularly relate to a kind of preparation method with nanometer level microporous block macromolecular material.Belong to polymer chemistry and technical field of polymer.
Background technology
Poly(lactic acid) (Polylactic acid, PEG) be that a new generation of developing rapidly the nineties in 20th century can degradable macromolecular material, it has good biocompatibility, class bio-medical material and environment-friendly materials of food and drug administration (Food and Drug Adiministration, FDA) approval.From the sixties in 20th century, scientific worker starts to pay close attention to the degradation property of poly-lactic acid material, and first using poly-lactic acid material as degradable operation stitching wire material.1966, (the Kricheldorf H. R. such as Kulkarni
chemospherein 2001,43,49-54., propose first: low-molecular-weight PEG can degradation in vivo, and final meta-bolites is CO
2and H
2o, harmless, environmentally safe.Simultaneously, by the research of poly(lactic acid) vivo degradation process is found, the intermediate product lactic acid of degraded is the product of eubolism in body, can not accumulate in vivo, therefore PEG can not produce detrimentally affect to organism after degrading in vivo, has caused thus and has usingd the beginning of this class material as bio-medical material.In recent years, it in medicine sustained and controlled release system, has more and more received the concern of scientists as pharmaceutical carrier.
But common line style poly(lactic acid) (Linear polylactic acid, LPEG) there are some shortcomings, for example its solution and bulk viscosity are higher, degree of crystallinity is large, material fragility is high, thermostability is low and low degradation speed, limited to a certain extent it in the widespread use in the fields such as medical, agricultural and packing, particularly at the application aspect Thermosensitive Material Used for Controlled Releasing of Medicine (Wang L., Dong C. M.
j. Polym. Sci. Part A:Polym. Chem.2006,44 (7), 2226-2236.).Star-like poly(lactic acid) (Star-shaped polylactic acids, SPEG) there is the short and molecular weight advantages of higher of side chain, its solution and bulk viscosity are more much lower than same molecular amount LPEG, mobility and solubility property improve, and its degradation speed is but fast than same molecular amount LPEG, thermostability is higher, is conducive to its processed and applied in the bio-medical materials such as medicament slow release.
No matter although line style or star-like poly-lactic acid material have been widely used in Thermosensitive Material Used for Controlled Releasing of Medicine and tissue engineering material aspect, but the restriction due to himself hydrophobic structure, also part comes with some shortcomings, for example its wetting ability is not good, degradation rate is slower, degradation cycle is difficult to regulation and control, and implant inner posterior quadrant easily adheres to material surface etc.Scientists has been carried out the research of the modification of configuration aspects to PEG material for these problems.In order to increase the wetting ability of PEG, common material modified have polyoxyethylene glycol (Polyethylene glycol, PEG) (Moffatt S., Cristiano R.
j. Int. J. Pharm.2006,317,10-13.), polyvinyl alcohol (Poly vinyl alcohol, PVA), dextran (dextran), chitosan and polypeptide (polypeptide) etc.Because polypeptide (also referred to as polyamino acid) is the biodegradable polymer of a class, have low toxicity, good biocompatibility, biodegradable, easily by body, absorbed and the advantage such as metabolism, Amino Acid Unit structure can be selected, hydrophilicity and hydrophobicity is adjustable, started to be applied in the study on the modification of poly(lactic acid), but only had seldom report.
On the other hand, multiporous biological degradable material is the brand-new material system that development in recent years is got up, and is a kind of material with network structure consisting of mutual perforation or blind hole hole, and the border of hole or surface consist of pillar or flat board.It has regularly arranged and big or small adjustable pore passage structure, relative density is low, specific tenacity is high, porosity and surface-area large, perviousness and excellent adsorption and good biocompatibility, the features such as environmental friendliness, are all with a wide range of applications with fields such as separated, nanomaterial assembly, biological chemistry, molecular recognition and pharmaceutical carriers in bulky molecular catalysis, absorption.By us, to the consulting of documents and materials, also there is no so far that a kind of poly-lactic acid material has that processing characteristics is high simultaneously, a feature such as wetting ability, good biodegradability, nanometer level microporous, high Drug loading capacity.
Summary of the invention
The object of the invention is to set up a kind of preparation method of pharmaceutical functional polyalkylene glycol, this polymer materials has the following advantages: good processability, wetting ability, good biodegradability, nanometer level microporous, high Drug loading capacity.
This polyoxyethylene glycol material is a kind of star-shaped polyethylene glycol/polypeptide segmented copolymer; Take oxyethane as raw material, the three arm polyoxyethylene glycol that utilized alkaline process ring opening synthesis; Prepare macromole evocating agent; Carry out ring-opening polymerization with O-benzyl-TYR carboxylic acid anhydride (NCA) and obtain take the star block copolymer that PEG is arm as the poly-O-benzyl-TYR of core; Add lower molecular weight polytyrosine, utilize the amphiphilic water of segmented copolymer to be dissolved, form nanoscale porous material.
The technology of preparing scheme of porous polyoxyethylene glycol material is as follows:
1) star-shaped polyethylene glycol is synthetic
2) macromole evocating agent is synthetic
3) preparation of star block copolymer
4) preparation method of polyglycol porous material is as shown in Figure of description 3
By above technical scheme, tool of the present invention has the following advantages: 1) this pharmaceutical functional polyalkylene glycol has nano micropore structure capable;
2) this pharmaceutical functional polyalkylene glycol has hexagonal columnar structure;
3) this pharmaceutical functional polyalkylene glycol has high drug loading amount, and good biocompatibility;
4) this pharmaceutical functional polyalkylene glycol has pharmaceutical carrier function and discharges pharmic function, can effectively reduce medicine normal tissue organ toxic side effect.
Accompanying drawing explanation
Fig. 1 is the vesicular structure schematic diagram of this polymer materials;
Fig. 2 is the electron photomicrograph of this polymer materials;
Fig. 3 is the preparation method of polyglycol porous material.
Embodiment
Provide embodiment below so that the present invention is specifically described; but it is worthy of note that following examples are only used to further illustrate the present invention; can not be interpreted as limiting the scope of the invention, some nonessential improvement that the person skilled in the art in this field makes the present invention according to the invention described above content and adjustment still belong to protection scope of the present invention.
Embodiment 1:
1. prepare star block copolymer
Take oxyethane as raw material; utilized classical alkaline process ring opening synthesis three arms or multi-arm star-shaped polyethylene glycol; existence due to the hydroxyl of polymer ends; can adopt the glycine of amino Boc-radical protection; under the catalysis of DCC/HOBt, react with SPEG and generate SPEG derivative; in trifluoracetic acid/dichloromethane solution, carry out the amino de-Boc protection of above-mentioned product, obtained the star-like macromole evocating agent SPEG-NH of end amido functional group
2.Macromole evocating agent and O-benzyl-TYR carboxylic acid anhydride (NCA) are carried out to ring-opening polymerization by a certain percentage, obtain take the star block copolymer that PEG is arm as the poly-O-benzyl-TYR of core.
2. the sign of star block copolymer material self-assembled structures and performance
The chemical structure of polymkeric substance and shape characteristic are the bases of the every character of Study Polymer Melts.This problem intends utilizing gel permeation chromatography (GPC), Fourier transform infrared spectroscopy (FTIR) and nucleus magnetic resonance (NMR) method detect chemical structure and the polymerization degree of polymkeric substance, utilize thermogravimetric analyzer (TGA) to study the thermal characteristics of polymkeric substance, the transformation mutually, the liquid crystal behavior that use differential scanning calorimeter (DSC) research segmented copolymer, utilize one dimension, two-dimentional wide-angle x-ray diffraction instrument (WAXD) to determine the phase structure of each segment in segmented copolymer.The star block copolymer proposing in this problem more easily forms micro phase separation structure, can utilize atomic force microscope (AFM) and transmission electron microscope (TEM) to observe star block copolymer at the self-assembled structures of substrate surface, utilize little angle one dimension, two-dimentional x-ray diffractometer (SAXS) to study the micro phase separation structure of star block copolymer.
3. the preparation of porous material
Obtain after required polyoxyethylene glycol/poly-O-benzyl-TYR star block copolymer, we will observe its body self-assembly behavior, mainly study its micro phase separation structure.Because the body microphase-separated self-assembled structures of segmented copolymer is relevant with the relative proportion that forms component, by the impacts of factor on the phase of micro phase separation structure and size such as content, molecular weight of research block component, we can determine may be applicable segmented copolymer to carry out aftertreatment.Particularly for the segmented copolymer that forms (six sides) column phase or co-continuous double helix phase, when material forms nano pore, and micro phase separation structure is arranged when even, material is higher for the release efficiency of medicine, during as embedded material and the contact area of body fluid increase, be conducive to improve the degradation speed of material.We as the impact on material micro phase separation structure such as solvent species, solvent evaporates speed, make poly-O-benzyl-TYR block in polymkeric substance outside form column or double-spiral structure to obtain top condition research material preparation condition.
The synthetic star block copolymer obtaining in a certain amount of lower molecular weight polytyrosine homopolymer and above-mentioned route is carried out to blend, can obtain the hexagonal columnar phase micro phase separation structure that we need, phase structure can be by confirmations such as low-angle scattering of X-rays and high-resolution electron microscopes.The impact of composition etc. by research blend on the phase of micro phase separation structure and size, we can select suitable blend to carry out aftertreatment.On the other hand, if multipolymer forms co-continuous double helix phase, also may be used as porous material.Then we,, by having the film water treatment of column phase or co-continuous double helix phase structure, dissolve polytyrosine homopolymer, just obtain the modified porous material of star-shaped polyethylene glycol containing hydrophilic nano duct, the carrier of useful as drug model compound.
4. porous star block copolymer is as the research of pharmaceutical carrier
This experiment is intended by existence form and the concentration of steady-state fluorescence spectral characterization and mensuration pyrene, with prove this based block copolymer whether can be in water solution system stable micro-molecular compound, and then discharge in EPC liposome, thereby explore this type of macromolecular material as the potential application of pharmaceutical carrier from the complex body of high-molecular block copolymer-pyrene.Main employing steady-state fluorescence spectroscopic analysis: the spectrum of all samples all records by right angle light path in 4 mL cuvettes.The spectrum of solid-state pyrene crystal is measured by solid support.While doing fluorescence emission spectrum mensuration, emission spectrum wavelength region is 350～650 nm, and excitation wavelength is 336 nm.Excitation spectrum records at emission wavelength 374 nm and 470 nm that represent pyrene monomer and excimer transmitting respectively.All scanning exciting light slits are made as 5 nm, and utilizing emitted light slit is made as 2.5 nm, and PMT voltage is all made as 400 volts, and sweep velocity is 240 nm/min, and spectrum correction is all made as opens to eliminate the wavelength dependency of grating and monitor response.Each Sample Scan is averaged for three times.Be determined at 25
ounder C, carry out.
Finally it should be noted that, above embodiment is only unrestricted in order to technical scheme of the present invention to be described, although the present invention is had been described in detail with reference to preferred embodiment, those of ordinary skill in the art should understand, can a minute technical scheme for invention be modified or be replaced on an equal basis, and not departing from the spirit and scope of technical solution of the present invention, it all should be encompassed in the middle of claim scope of the present invention.
Claims (7)
1. a pharmaceutical functional polyalkylene glycol, its constitutional features is: described macromolecular material is the star-like type multipolymer being formed by hydrophobicity polyoxyethylene glycol segment and the poly-O-benzyl-TYR segment coupling of wetting ability.
2. a method of preparing pharmaceutical functional polyalkylene glycol claimed in claim 1 is carried out as follows:
1) take oxyethane as raw material, the three arm polyoxyethylene glycol that utilized pungent alkaline process ring opening synthesis;
2) prepare macromole evocating agent;
3) carry out ring-opening polymerization with O-benzyl-TYR carboxylic acid anhydride and obtain take the star block copolymer that polyoxyethylene glycol is arm as the poly-O-benzyl-TYR of core;
4) add lower molecular weight polytyrosine, utilize the amphiphilic water of segmented copolymer to be dissolved, form nanoscale porous material.
3. the preparation method of a kind of pharmaceutical functional polyalkylene glycol according to claim 2, is characterized in that the catalyzer that in aforesaid method, star-type polymer that step 1) is closed is used is stannous octoate.
4. the preparation method of a kind of pharmaceutical functional polyalkylene glycol according to claim 2, is further characterized in that the polymerization single polymerization monomer that in aforesaid method, step 3) is used is O-benzyl-TYR carboxylic acid anhydride.
5. the preparation method of a kind of pharmaceutical functional polyalkylene glycol according to claim 2, is further characterized in that in the ring-opening polymerization that in aforesaid method, step 3) is carried out and uses primary amine to carry out polyreaction as initiator.
6. a kind of pharmaceutical functional polyalkylene glycol according to claim 2, is further characterized in that: this macromolecular material is polyoxyethylene glycol and the formed porous material of poly-O-benzyl-TYR.
7. a kind of pharmaceutical functional polyalkylene glycol according to claim 2, is further characterized in that: described porous polymer materials has hexagonal columnar structure clearly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410331977.1A CN104072758A (en) | 2014-07-13 | 2014-07-13 | Functional polyethylene glycol (PEG) for medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410331977.1A CN104072758A (en) | 2014-07-13 | 2014-07-13 | Functional polyethylene glycol (PEG) for medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104072758A true CN104072758A (en) | 2014-10-01 |
Family
ID=51594387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410331977.1A Pending CN104072758A (en) | 2014-07-13 | 2014-07-13 | Functional polyethylene glycol (PEG) for medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104072758A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1687197A (en) * | 2005-04-18 | 2005-10-26 | 武汉大学 | Nano granules of ampyhiphilic three block copolymer preparation method and application |
| EP1792927A1 (en) * | 2004-09-22 | 2007-06-06 | Nippon Kayaku Kabushiki Kaisha | Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient |
-
2014
- 2014-07-13 CN CN201410331977.1A patent/CN104072758A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1792927A1 (en) * | 2004-09-22 | 2007-06-06 | Nippon Kayaku Kabushiki Kaisha | Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient |
| CN1687197A (en) * | 2005-04-18 | 2005-10-26 | 武汉大学 | Nano granules of ampyhiphilic three block copolymer preparation method and application |
Non-Patent Citations (1)
| Title |
|---|
| KANG WANG ET AL: "Novel Vesicles Self-Assembled From Amphiphilic Star-Armed PEG/Polypeptide Hybrid Copolymers for Drug Delivery", 《MACROMOLECULAR BIOSCIENCE》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Treesuppharat et al. | Synthesis and characterization of bacterial cellulose and gelatin-based hydrogel composites for drug-delivery systems | |
| Yang et al. | Fabrication and characterization of a novel polysaccharide based composite nanofiber films with tunable physical properties | |
| Fustin et al. | Triblock terpolymer micelles: A personal outlook a | |
| Naeini et al. | Poly (citric acid)-block-poly (ethylene glycol) copolymers—new biocompatible hybrid materials for nanomedicine | |
| Lambermont-Thijs et al. | Selective partial hydrolysis of amphiphilic copoly (2-oxazoline) s as basis for temperature and pH responsive micelles | |
| Phaechamud et al. | Pore formation mechanism of porous poly (dl-lactic acid) matrix membrane | |
| Martel-Estrada et al. | Synthesis and thermo-physical properties of chitosan/poly (dl-lactide-co-glycolide) composites prepared by thermally induced phase separation | |
| JP2003055460A (en) | Amphipathic biodegradable block copolymer having polyethyleneimine as hydrophilic block and polyester based polymer as hydrophobic block and self-associated polymer aggregate formed therefrom in aqueous environment | |
| CN103992475A (en) | Biocompatible degradable porous polyethylene glycol material | |
| Nguyen et al. | Reverse micelles prepared from amphiphilic polylactide-b-poly (ethylene glycol) block copolymers for controlled release of hydrophilic drugs | |
| CN104072707A (en) | Method for preparing star-shaped block copolymer porous drug carrier | |
| CN103980487A (en) | Preparation method for degradable porous polyethylene glycol | |
| CN104086722A (en) | Method for preparing biological porous material | |
| CN104059207A (en) | Acrylic acid and polyactic acid (PAA) contained functional polymer material | |
| EP2150237A1 (en) | Method for the preparation of biocompatible polymeric nanoparticles for drug delivery and nanoparticles prepared thereby | |
| Yang et al. | Self-assembling of biocompatible BAB amphiphilic triblock copolymers PLL (Z)–PEG–PLL (Z) in aqueous medium | |
| CN104072701A (en) | Method for synthesizing ABC multiblock copolymer drug polymer | |
| CN104086723A (en) | Multiblock multifunctional medicinal macromolecular material | |
| CN104059206A (en) | Preparation method of multifunctional medicinal polylactic acid (PLA) derivative ABC triblock polymer | |
| CN104448807A (en) | Degradable porous poly lactic acid preparation method | |
| Yang et al. | Preparation of poly (L-lactic acid) nanofiber scaffolds with a rough surface by phase inversion using supercritical carbon dioxide | |
| CN104109255A (en) | Novel medical polyethylene glycol (PEG) functional material | |
| CN104109239A (en) | Medical microporous polyethylene glycol (PEG) material | |
| CN104072702A (en) | Polylactic acid (PLA) containing block copolymer macromolecular material for medicine | |
| CN104086724A (en) | Novel hexagonal-pore medical biomaterial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20141001 |